Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Tristan Knight, MD, Xinan Qiao, BS, Jun Ma, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Kathryn White, Hai Lin, MD, Yue Wang, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2019) 134 (Supplement_1): 1262.

https://doi.org/10.1182/blood-2019-123793

Published: 2019

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia

Yongwei Su, Xinyu Li, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Katie Hege, Yu Fukuda, John D. Schuetz, PhD, Joshua E. Allen, PhD, Martin Stogniew, Varun Vijay Prabhu, BPharm, MS, PhD, Jeffrey W. Taub, MD, Hai Lin, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 3936.

https://doi.org/10.1182/blood-2018-99-116997

Published: 2018

Journal Articles

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Blood (2018) 132 (Supplement 1): 543.

https://doi.org/10.1182/blood-2018-99-116661

Published: 2018

Journal Articles

Inhibition of ATR Potentiates Acute Myeloid Leukemia Cells to the RNA Pol I Transcription Inhibitor CX-5461

Margaret Shatara, MD, Tingting Wang, Xinyu Li, Holly Edwards, BS, Jeffrey W. Taub, MD, Hai Lin, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 5224.

https://doi.org/10.1182/blood-2018-99-113937

Published: 2018

Journal Articles

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia

Daniel A Luedtke, BS, Yongwei Su, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Hai Lin, MD, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 1361.

https://doi.org/10.1182/blood-2018-99-118372

Published: 2018

Journal Articles

Novel Therapy for FLT3-ITD Acute Myeloid Leukemia Utilizing the Combination of CUDC-907 and Gilteritinib

Tristan Knight, MD, Xinan Qiao, BS, Holly Edwards, BS, Hai Lin, MD, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 1427.

https://doi.org/10.1182/blood-2018-99-111177

Published: 2018

Journal Articles

A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemic Pathogenesis

Andrew Volk, PhD, Kaiwei Liang, PhD, Jianyun Zhao, Xinyu Li, Marinka Bulic, Stacy Marshall, Jeffrey W. Taub, MD, Yubin Ge, PhD, Sebastien Malinge, PhD, Elizabeth Bartom, PhD, Ali Shilatifard, PhD, John D. Crispino, PhD

Blood (2017) 130 (Supplement 1): 245.

https://doi.org/10.1182/blood.V130.Suppl_1.245.245

Published: 2017

Journal Articles

Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia

Daniel A Luedtke, BS, Yongwei Su, Holly Edwards, Hai Lin, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 3819.

https://doi.org/10.1182/blood.V130.Suppl_1.3819.3819

Published: 2017

Journal Articles

ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells In Vitro and In Vivo

Yongwei Su, Xinyu Li, Holly Edwards, Joshua E. Allen, PhD, Martin Stogniew, Varun Vijay Prabhu, BPharm, MS, PhD, Jeffrey W. Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 3822.

https://doi.org/10.1182/blood.V130.Suppl_1.3822.3822

Published: 2017

Journal Articles

Targeting PI3K, mTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

Yongwei Su, Xinyu Li, Jianyun Zhao, Jun Ma, Shuang Liu, Holly Edwards, Jeffrey W. Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 1255.

https://doi.org/10.1182/blood.V130.Suppl_1.1255.1255

Published: 2017

Journal Articles

Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo

Xinyu Li, Jun Ma, Yongwei Su, Jianyun Zhao, Holly Edwards, Yue Wang, Jay Yang, MD, Jeffrey W Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2016) 128 (22): 1571.

https://doi.org/10.1182/blood.V128.22.1571.1571

Published: 2016

Journal Articles

Learning Not to Judge a Book By Its Cover: A Case Series of Malignancy Masquerading As Common Presentations of Sickle Cell Disease

Ahmar Urooj Zaidi, MD, Lo'Rell Martin, DO, Michael U Callaghan, MD, Sharada A. Sarnaik, MD, Jeffrey W Taub, MD

Blood (2016) 128 (22): 4872.

https://doi.org/10.1182/blood.V128.22.4872.4872

Published: 2016

Journal Articles

Binding of Released Bim to Mcl-1 Is Responsible for Resistance to ABT-199 Which Can be Overcome By Combination with Daunorubicin or Cytarabine in Acute Myeloid Leukemia Cells

Xiaojia Niu, Jianyun Zhao, Jun Ma, Chengzhi Xie, Holly Edwards, Guan Wang, J. Timothy Caldwell, Roland Chu, Zhihong Wang, MD PhD, Hai Lin, Jeffrey W Taub, MD, Yubin Ge, PhD

Blood (2015) 126 (23): 1265.

https://doi.org/10.1182/blood.V126.23.1265.1265

Published: 2015

Journal Articles

Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells

Jianyun Zhao, Xiaojia Niu, Holly Edwards, Yue Wang, Jeffrey W Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2015) 126 (23): 2469.

https://doi.org/10.1182/blood.V126.23.2469.2469

Published: 2015

Journal Articles

Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children’s Oncology Group (COG) Phase III AAML0431 Trial

Jeffrey W Taub, MD, Jason N Berman, MD, Johann K. Hitzler, MD, April D. Sorrell, MD, Norman J. Lacayo, MD, Kelley Mast, MD, David R. Head, MD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Robert B. Gerbing, MA, Todd A. Alonzo, PhD, Dario Campana, MD PhD, Elaine Coustan-Smith, MS, Prasad Mathew, Alan S. Gamis, MD MPH

Blood (2014) 124 (21): 278.

https://doi.org/10.1182/blood.V124.21.278.278

Published: 2014

Journal Articles

Targeting The Wee1 Kinase With MK-1775 For Treatment Of Acute Myeloid Leukemia In The Down Syndrome Population

J. Timothy Caldwell, Steven A Buck, Yubin Ge, PhD, Jeffrey W Taub, MD

Blood (2013) 122 (21): 3836.

https://doi.org/10.1182/blood.V122.21.3836.3836

Published: 2013

Journal Articles

Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy

Seth E Karol, MD, Elaine Coustan-Smith, MS, Xueyuan Cao, PhD, Sheila A Shurtleff, PhD, Susana C Raimondi, PhD, John K Choi, MD, PhD, Raul C Ribeiro, MD, Gary V Dahl, MD, W Paul Bowman, MD, Jeffrey W Taub, MD, Barbara Degar, MD, Wing Leung, MD, PhD, James R Downing, MD, Ching-Hon Pui, MD, Jeffrey E Rubnitz, MD, PhD, Dario Campana, MD, PhD, Hiroto Inaba, MD, PhD

Blood (2013) 122 (21): 490.

https://doi.org/10.1182/blood.V122.21.490.490

Published: 2013

Journal Articles

AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia

Todd Cooper, DO, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., John Perentesis, MD, James A. Whitlock, MD, Jeffrey W. Taub, MD, Terzah M. Horton, MD, PhD, Alan S. Gamis, MD, MPH, Bassem I. Razzouk, MD

Blood (2012) 120 (21): 3604.

https://doi.org/10.1182/blood.V120.21.3604.3604

Published: 2012

Journal Articles

Altered Folate Metabolism Maybeo the Develop Linked tment of Acute Lymphoblastic Leukemia in African American Children.

Qing Chen, MD, Nancy Fassinger, RD, PhD, Ronald Thomas, PhD, Ana C. Xavier, MD, Yubin Ge, PhD, Larry H. Matherly, PhD, Jeffrey W. Taub, MD

Blood (2009) 114 (22): 4118.

https://doi.org/10.1182/blood.V114.22.4118.4118

Published: 2009

NARROW

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Inhibition of ATR Potentiates Acute Myeloid Leukemia Cells to the RNA Pol I Transcription Inhibitor CX-5461

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia

Novel Therapy for FLT3-ITD Acute Myeloid Leukemia Utilizing the Combination of CUDC-907 and Gilteritinib

A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemic Pathogenesis

Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia

ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells In Vitro and In Vivo

Targeting PI3K, mTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo

Learning Not to Judge a Book By Its Cover: A Case Series of Malignancy Masquerading As Common Presentations of Sickle Cell Disease

Binding of Released Bim to Mcl-1 Is Responsible for Resistance to ABT-199 Which Can be Overcome By Combination with Daunorubicin or Cytarabine in Acute Myeloid Leukemia Cells

Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells

Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children’s Oncology Group (COG) Phase III AAML0431 Trial

Targeting The Wee1 Kinase With MK-1775 For Treatment Of Acute Myeloid Leukemia In The Down Syndrome Population

Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy

AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia

Altered Folate Metabolism Maybeo the Develop Linked tment of Acute Lymphoblastic Leukemia in African American Children.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only